
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. demonstrates a positive outlook due to the encouraging preliminary results from the FREEDOM-DM1 trial, which showcased a dose-dependent increase in splicing correction and a significant four-fold enhancement in oligonucleotide enrichment in muscle tissue. The company's Enhanced Delivery Oligonucleotide (EDO) platform has shown robust efficacy while maintaining strong safety profiles, with the current data indicating potential therapeutic benefits in the DM1 landscape, especially as they plan to escalate dosing to 20 mg/kg. Furthermore, the reliable efficacy metrics, including a 29.1% splicing correction surpassing the crucial therapeutic threshold, support a favorable long-term view on the company’s ability to innovate within the neuromuscular disease treatment space.
Bears say
PepGen Inc reported a net loss of $22 million, translating to a loss of $0.68 per share in the fourth quarter, indicating significant financial strain on the company. The probability of success for its lead product, PGN-EDO51, has been lowered from 40% to 25% due to safety concerns, particularly related to kidney function as evidenced by decreased estimated glomerular filtration rate (eGFR) among study participants. Furthermore, multiple risks threaten the future of PGN-EDO51, including potential failures in clinical studies, regulatory approvals in key markets (US and EU), and challenges in achieving projected peak commercial revenues.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares